20 results on '"Liu, Binliang"'
Search Results
2. Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody
3. Overexpressed SIRT6 ameliorates doxorubicin-induced cardiotoxicity and potentiates the therapeutic efficacy through metabolic remodeling
4. Subtyping of metastatic breast cancer based on plasma circulating tumor DNA alterations: An observational, multicentre platform study
5. The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study.
6. The molecular tumor burden index as a response evaluation criterion in breast cancer
7. Breast cancer metastases to the thyroid and stomach: A case report
8. Knowledge level of cardio-oncology in oncologist and cardiologist: a survey in China
9. Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC
10. Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer
11. The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
12. Focus on anticancer therapy-induced cardiotoxicity from the perspective of oncologists
13. Clinical value of next-generation sequencing in endocrine therapy for advanced hormone receptor–positive/HER2-negative breast cancer.
14. Peripheral lipidomics analyses with ensemble machine learning predict response to neoadjuvant therapy in breast cancer.
15. Clinical and genetic predictions of early-onset cardiac toxicity in adjuvant chemotherapy for breast cancer
16. Molecular landscape ofTP53mutations in breast cancer and their utility for predicting the response to HER ‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
17. Antibody-drug conjugates in HER2-positive breast cancer
18. Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients.
19. Antibody-drug conjugates in HER2-positive breast cancer
20. Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.